EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?

Eur J Health Econ. 2018 Sep;19(7):905-907. doi: 10.1007/s10198-017-0944-0.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Drug Approval / economics
  • Drug Approval / methods*
  • Drug Costs
  • Drug Industry
  • European Union
  • Humans
  • Reimbursement, Incentive* / economics
  • Reimbursement, Incentive* / organization & administration